Chemopreventive activity of lantadenes on two-stage carcinogenesis model in Swiss albino mice: AP-1 (c-jun), NFκB (p65) and P53 expression by ELISA and immunohistochemical localization

  • Jagdeep Kaur
  • Manu Sharma
  • P. D. Sharma
  • M. P. Bansal


Lantadenes are pentacyclic triterpenoids isolated from leaves of Lantana camara L. and have antitumor activity. Lantadene A (LA) and methyl ester of LA (LAM) were earlier studied in the author’s lab for their chemopreventive effect on 7,12-dimethylbenz(a)anthracene (DMBA) followed by 12–O-tetradecanoylphorbol-13-acetate (TPA) induced squamous cell carcinoma incidence in Swiss albino mice. The present study was specially designed to initiate the involvement of the molecular targets in chemopreventive activity of these compounds. Skin lesions were induced by twice-weekly topical application of DMBA (100 nmol/100 μl of acetone) for 2 weeks followed by TPA (1.7 nmol/100 μl of acetone) on depilated back of mice for 20 weeks. LA and LAM were administered orally at a dose of 50 mg/kg body weight twice weekly, 1 week before DMBA application and continued for 20 weeks thereafter. A significant decrease in the incidence of number of lesions in mice was obtained in LA/LAM treated groups as compared to DMBA/TPA alone. Significant increase in the protein levels of c-jun, p65, and p53 by ELISA were observed in DMBA/TPA treated mice tumors whereas less expression was observed in LA and LAM treated tumors. Further immunohistochemical localization of transcription factors was studied which also showed less localization of c-jun, p65, and p53 in LA and LAM treated tumors as compared to localization in DMBA/TPA treated tumors. It can be inferred that LA and LAM chemopreventive activity may be linked to the deregulation of above molecular targets which warrants further studies in that direction.


Transcription factors Lantadenes Squamous cell carcinoma 


  1. 1.
    Parker JN, Zhao W, Askins KJ, Broker TR, Chow LT (1997) Mutational analyses of differentiation-dependent human papillomavirus type 18 enhancer elements in epithelial raft cultures of neonatal foreskin keratinocytes. Cell Growth Differ 8:751–762PubMedGoogle Scholar
  2. 2.
    Holeb AI, Fink DJ, Murphy GP (1991) American cancer society textbook of clinical oncology. Atlana American Cancer Society Inc., pp 456–465Google Scholar
  3. 3.
    Shimada T (2006) Xenobiotic-metabolizing enzymes involved in activation and detoxification of carcinogenic polycyclic aromatic hydrocarbons. Drug Metab Pharmacokinet 21:257–276PubMedCrossRefGoogle Scholar
  4. 4.
    Siebenlist U, Franzoso G, Brown K (1994) Structure, regulation and function of NF-kappa B. Annu Rev Cell Biol 10:405–455PubMedCrossRefGoogle Scholar
  5. 5.
    Angel P, Szabowski A, Schorpp-Kistner M (2001) Function and regulation of AP-1 subunits in skin physiology and pathology. Oncogene 20:2413–2423PubMedCrossRefGoogle Scholar
  6. 6.
    Shaulian E, Karin M (2002) AP-1 as a regulator of cell life and death. Nat Cell Biol 4:131–136CrossRefGoogle Scholar
  7. 7.
    Jochum W, Passegué E, Wagner EF (2001) AP-1 in mouse development and tumorigenesis. Oncogene 20:2401–2412PubMedCrossRefGoogle Scholar
  8. 8.
    Ozanne BW, McGarry L, Spence HJ, Johnston I et al (2000) Transcriptional regulation of cell invasion: AP-1 regulation of a multigenic invasion programme. Eur J Cancer 36:1640–1648PubMedCrossRefGoogle Scholar
  9. 9.
    Suzuki T, Murakami M, Onai N, Fukuda F et al (1994) Analysis of AP-1 function in cellular transformation pathways. J Virol 68:3527–3535PubMedGoogle Scholar
  10. 10.
    Lamb RF, Hennigan RF, Turnbull K, Katsanakis KD, MacKenzie ED, Birnie GD et al (1997) AP-1-mediated invasion requires increased expression of the hyaluronan receptor CD44. Mol Cell Biol 17:963–976PubMedGoogle Scholar
  11. 11.
    Bone RC, Balk RA, Cerra FB et al (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies for sepsis. The ACCP/SCCM Conference Committee, American College of Chest Physicians/Society of Critical Care Medium. Chest 101:1644–1655PubMedCrossRefGoogle Scholar
  12. 12.
    Ben-Shaul V, Lomintski L, Nyska A, Zurovsky Y, Berman M, Grossman S (2001) The effect of natural antioxidants, NAO and apocynin on oxidative stress in the rat heart following LPS challenge. Toxicol Lett 123:1–10PubMedCrossRefGoogle Scholar
  13. 13.
    Barnes PJ (1997) Nuclear factor-κB. Int J Biochem Cell Biol 29:867–870PubMedCrossRefGoogle Scholar
  14. 14.
    Levesque AA, Eastman A (2007) p53-based cancer therapies: is defective p53 the Achilles heel of the tumor? Carcinogenesis 28:13–20PubMedCrossRefGoogle Scholar
  15. 15.
    Wattenberg LW (1997) An overview of chemoprevention: current status and future prospects. Proc Soc Exp Biol Med 216:133–141PubMedGoogle Scholar
  16. 16.
    Singh DK, Lippman SM (1998) Cancer Chemoprevention, Part 1: retinoids and carotenoids and other classical antioxidants. Oncology (Willison Park) 12:1643–1660Google Scholar
  17. 17.
    Abdullaev GI (2001) Plant derived agent against cancer. In: Gupta SK (ed) Pharmacology and therapeutics in the new millennium, Narosa Publishing House, New Delhi, pp 345–354Google Scholar
  18. 18.
    Kellof GJ, Boone CW, Crowell JA, Steel VE, Luvet R, Sigmen CC (1994) Chemopreventive drug development: perspectives and progress. Cancer Epidemiol Biomarkers Prev 3:85–98Google Scholar
  19. 19.
    Sharma OP, Vaid J, Sharma PD (1991) Natural products of the lantana plant- the present & prospects. J Sci Ind Res 48:471–478Google Scholar
  20. 20.
    Liu J (1995) Pharmacology of oleanolic acid and ursolic acid. J Ethnopharmacol 40:57–60CrossRefGoogle Scholar
  21. 21.
    Sharma M, Sharma PD (2006) Optimization of lantadene isolation & preparation of 22 β-hydroxy oleanolic acid. Chem Nat Comp 42:442–446CrossRefGoogle Scholar
  22. 22.
    Inada A, Nakanishi T, Tokuda H, Nishino H, Iwashina A, Sharma OP (1995) Inhibitory effects of Lantadenes & related triterpinoids on Epstein-Barr virus activation. Planta Med 61:558–560PubMedCrossRefGoogle Scholar
  23. 23.
    Inada A, Nakanishi T, Tokuda T, Nishino H, Iwashina A, Sharma OP (1997) Anti-tumor promoting activities of Lantadenes on mouse skin tumors & mouse hepatic tumors. Planta Med 63:272–274PubMedCrossRefGoogle Scholar
  24. 24.
    Sharma M, Sharma PD, Bansal MP (2007) Chemopreventive effect of Lantana camara leaf extract on 7,12-Dimethylbenz[a]anthracene-induced squamous cell carcinoma of skin in swiss albino mice. Pharma Biol 45:145–148CrossRefGoogle Scholar
  25. 25.
    Azuine MA, Bhide SV (1992) Chemopreventive effect of turmeric against stomach and tumors induced by chemical carcinogenesis in Swiss albino mice. Nutr Cancer 17:77–83PubMedGoogle Scholar
  26. 26.
    Lowry OH, Rosenbrough NJ, Farr AL, Randell RJ (1955) Protein measurement with folin-phenol reagent. J Biol Chem 193:265–275Google Scholar
  27. 27.
    Hess J, Angel P, Schorpp-Kistner M (2004) AP-1 subunits: quarrel and harmony among siblings. J Cell Sci 117:5965–5973PubMedCrossRefGoogle Scholar
  28. 28.
    Aggarwal BB, Sethi G, Nair A, Ichikawa H (2006) Nuclear factor-κB: a holy grail in cancer prevention and therapy. Curr Sig Trans Therapy 1:25–52CrossRefGoogle Scholar
  29. 29.
    Asehnoune K, Strassheim D, Mitra S, Yeol-Kim M, Abraham E (2004) Involvement of reactive oxygen species in Toll-like receptor 4-dependent activation of NF-kappaB. J Immunol 172:2522–2529PubMedGoogle Scholar
  30. 30.
    Asakura M, Kitakaze M, Takashima S et al (2002) Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as new therapy. Nat Med 8:35–40PubMedCrossRefGoogle Scholar
  31. 31.
    Bharti AC, Donato N, Singh S, Aggarwal BB (2003) Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and I kappa B alpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood 101:1053–1062PubMedCrossRefGoogle Scholar
  32. 32.
    Agarwal ML, Taylor WR, Chernov MV, Chernova OB, Stark GR (1998) The p53 network. J Biol Chem 273:1–4PubMedCrossRefGoogle Scholar
  33. 33.
    Mowat MR (1998) p53 in tumor progression: life, death and everything. Adv Cancer Res 74:25–48PubMedCrossRefGoogle Scholar
  34. 34.
    Arora A, Siddiqui IA, Shuklka Y (2004) Modulation of p53 in 7,12-dimethylbenz[a]anthracene-induced skin tumors by diallyl sulfide in Swiss albino mice. Mol Cancer Ther 3:1459–1466PubMedGoogle Scholar
  35. 35.
    Shin DM, Xu XC, Lippman SM et al (1997) Accumulation of p53 protein and retinoic acid receptor beta in retinoid chemoprevention. Clin Cancer Res 3:875–880PubMedGoogle Scholar
  36. 36.
    Huang H, Ma WY, Goranson A, Dong Z (1999) Resveratrol suppresses cell transformation and induces apoptosis through a p53-dependent pathway. Carcinogenesis 20:237–242PubMedCrossRefGoogle Scholar
  37. 37.
    She QB, Bode M, Ma WY, Chen NY, Dong Z (2001) Resveratrol-induced activation of p53 and apoptosis is mediated by extracellular-signal-regulated protein kinases and p38 kinase. Cancer Res 61:1604–1610PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2008

Authors and Affiliations

  • Jagdeep Kaur
    • 1
  • Manu Sharma
    • 2
  • P. D. Sharma
    • 2
  • M. P. Bansal
    • 1
  1. 1.Department of BiophysicsPanjab UniversityChandigarhIndia
  2. 2.University Institute of Pharmaceutical SciencesPanjab UniversityChandigarhIndia

Personalised recommendations